[go: up one dir, main page]

CY1109001T1 - Kappa-like Fighters in the Treatment of Cystic Diseases - Google Patents

Kappa-like Fighters in the Treatment of Cystic Diseases

Info

Publication number
CY1109001T1
CY1109001T1 CY20071101231T CY071101231T CY1109001T1 CY 1109001 T1 CY1109001 T1 CY 1109001T1 CY 20071101231 T CY20071101231 T CY 20071101231T CY 071101231 T CY071101231 T CY 071101231T CY 1109001 T1 CY1109001 T1 CY 1109001T1
Authority
CY
Cyprus
Prior art keywords
treatment
fighters
kappa
cystic diseases
medicament
Prior art date
Application number
CY20071101231T
Other languages
Greek (el)
Inventor
Jutta Jacob
Frank Weber
Gerd Bartoszyk
Christoph Seyfried
Original Assignee
Tioga Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tioga Pharmaceuticals, Inc. filed Critical Tioga Pharmaceuticals, Inc.
Publication of CY1109001T1 publication Critical patent/CY1109001T1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η ευρεσιτεχνία αφορά τη χρήση του φαρμάκου Ν-μεθυλο-Ν[(1S)-1-φαινυλο-2-((3S)-3-υδροξυπυρρολιδιν-1-υλο)αιθυλο]-2,2-διφαινυλο-ακεταμίδιο ή ενός από τα φαρμακολογικά αποδεκτά άλατά του με σκοπό τη παρασκευή ενός φαρμακευτικού σκευάσματος για τη θεραπεία των παθήσεων της κύστης, ιδιαίτερα της ερεθισμένης κύστης και των πόνων που συνδέονται με αύτή.The invention relates to the use of the medicament N-methyl-N [(1S) -1-phenyl-2 - ((3S) -3-hydroxypyrrolidin-1-yl) ethyl] -2,2-biphenyl acetamide or one of the pharmacologically acceptable salts thereof for the preparation of a medicament for the treatment of bladder diseases, in particular irritable bladder and associated pain.

CY20071101231T 2001-04-05 2007-09-25 Kappa-like Fighters in the Treatment of Cystic Diseases CY1109001T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10116978A DE10116978A1 (en) 2001-04-05 2001-04-05 Kappa opiate agonists for the treatment of diseases of the bladder
EP02724228A EP1397128B1 (en) 2001-04-05 2002-03-13 Kappa opoid agonist for the treatment of irritable bladder

Publications (1)

Publication Number Publication Date
CY1109001T1 true CY1109001T1 (en) 2014-07-02

Family

ID=7680492

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101231T CY1109001T1 (en) 2001-04-05 2007-09-25 Kappa-like Fighters in the Treatment of Cystic Diseases

Country Status (23)

Country Link
US (1) US20040157913A1 (en)
EP (2) EP1834640A3 (en)
JP (1) JP2004525165A (en)
KR (1) KR100851938B1 (en)
CN (1) CN1268332C (en)
AT (1) ATE366109T1 (en)
AU (1) AU2002254947B2 (en)
BR (1) BR0208488A (en)
CA (1) CA2443019C (en)
CY (1) CY1109001T1 (en)
CZ (1) CZ20032899A3 (en)
DE (2) DE10116978A1 (en)
DK (1) DK1397128T3 (en)
ES (1) ES2290286T3 (en)
HU (1) HUP0303910A3 (en)
MX (1) MXPA03009099A (en)
MY (1) MY136683A (en)
PL (1) PL363540A1 (en)
PT (1) PT1397128E (en)
RU (1) RU2307651C2 (en)
SK (1) SK13272003A3 (en)
WO (1) WO2002080905A1 (en)
ZA (1) ZA200308600B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259245A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivatives of asimadolin with covalently bound acids
WO2005046687A1 (en) * 2003-10-30 2005-05-26 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
PT2136801E (en) 2007-03-30 2012-12-06 Tioga Pharmaceuticals Inc Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
BR112014020271A8 (en) * 2012-03-19 2017-07-11 Wellesley Pharmaceuticals Llc PHARMACEUTICAL COMPOSITION AND METHODS TO DECREASE URINATION FREQUENCY IN PATIENTS
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
CN112703000B (en) 2018-07-23 2024-05-31 特雷维治疗股份有限公司 Treatment of chronic cough, shortness of breath, and difficulty breathing
AU2021206252A1 (en) 2020-01-10 2022-07-28 Trevi Therapeutics, Inc. Methods of administering nalbuphine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
DE4215213A1 (en) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
DE19523502A1 (en) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa opiate agonists for inflammatory bowel diseases
DE19531464A1 (en) * 1995-08-26 1997-02-27 Merck Patent Gmbh N-methyl-N - [(1S -) - 1-phenyl-2 - ((3S) -3-hydroxypyrrolidin 1-yl -) - ethyl] -2,2-diphenyl-acetamide
US5859043A (en) * 1996-06-11 1999-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for maintaining kidney function during surgery or severe trauma under general anesthesia
US6201022B1 (en) * 1997-03-27 2001-03-13 Myorx, Inc. Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid
US5965701A (en) 1997-12-23 1999-10-12 Ferring Bv Kappa receptor opioid peptides

Also Published As

Publication number Publication date
PL363540A1 (en) 2004-11-29
MXPA03009099A (en) 2004-02-12
ZA200308600B (en) 2004-09-13
CA2443019A1 (en) 2002-10-17
SK13272003A3 (en) 2004-02-03
EP1834640A2 (en) 2007-09-19
CA2443019C (en) 2009-12-29
US20040157913A1 (en) 2004-08-12
EP1397128B1 (en) 2007-07-04
HUP0303910A3 (en) 2005-04-28
ATE366109T1 (en) 2007-07-15
RU2003130641A (en) 2005-03-10
DE10116978A1 (en) 2002-10-10
DK1397128T3 (en) 2007-10-15
AU2002254947B2 (en) 2007-06-07
RU2307651C2 (en) 2007-10-10
DE50210422D1 (en) 2007-08-16
EP1397128A1 (en) 2004-03-17
HK1064036A1 (en) 2005-01-21
MY136683A (en) 2008-11-28
JP2004525165A (en) 2004-08-19
CN1499967A (en) 2004-05-26
CZ20032899A3 (en) 2004-06-16
EP1834640A3 (en) 2009-12-23
CN1268332C (en) 2006-08-09
KR20040025909A (en) 2004-03-26
PT1397128E (en) 2007-09-03
ES2290286T3 (en) 2008-02-16
WO2002080905A1 (en) 2002-10-17
KR100851938B1 (en) 2008-08-12
HUP0303910A2 (en) 2004-03-29
BR0208488A (en) 2004-03-02

Similar Documents

Publication Publication Date Title
CY1109001T1 (en) Kappa-like Fighters in the Treatment of Cystic Diseases
CY1109119T1 (en) PHARMACEUTICAL FORMS OF LONG-TERM RELEASE INCLUDING LAMOTRIGIN
CY1110019T1 (en) Combined Therapy with Substituted Oxazolidinones
CY1107838T1 (en) ADAMANTANIUM PRODUCTION FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL AND CARDIOGRAPHIC DISEASES
CY1116693T1 (en) A combination of azelastin and cycloneside
EA200101156A1 (en) DRUG COMPOSITIONS OF A NEW TYPE ON THE BASIS OF POSSESSING HOLYNTHERGIC ACTION OF COMPOUNDS AND β-MIMETIC
PT1333887E (en) METHOD OF TREATMENT OF MUSCULAR DISORDERS
TW200505881A (en) Tri(cyclo) substituted amide compounds
AR032293A1 (en) PHARMACEUTICAL CASE
DE602004022946D1 (en) 4-Cyano-pyrazole-3-carboxylic acid amide derivatives, preparation and therapeutic use thereof
DE60336664D1 (en) NONNUCLEOSIDIC REVERSE TRANSCRIPTASE INHIBITORS
NO20065904L (en) Therapeutic compounds
CY1105941T1 (en) RARγ-SELECTIVE RETINOID AGENTS FOR THE TREATMENT OF EMPHYSEMA
DE50005529D1 (en) ORAL PHARMACEUTICAL FORMS FOR ADMINISTRATING A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC
DE60307632D1 (en) PIPERAZINYLACYLPIPERIDIN DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
ATE262893T1 (en) DOSAGE FORMS FOR THE TREATMENT OF ORAL MYCOSES
CY1107231T1 (en) Substituted 4-Aminocyclohexanol derivatives
CY1107465T1 (en) MELAGATRANI FOR THERAPEUTIC INFECTION
SE9902597D0 (en) New use
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
CY1105165T1 (en) PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METFORMIN AND 4-OXOBUTANOIC ACID AND ITS USE FOR THE TREATMENT OF DIABETES
BG105984A (en) Osanetant in the treatment of mood disorders
CY1105317T1 (en) USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE
CY1105142T1 (en) USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE
EA200500175A1 (en) SALT MORFIN-6-GLUCURONIDE